6-K - GELS - Equibles

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of December 2025

Commission File Number: 001-42373

Gelteq Limited

(Registrant’s Name)

Level 19

644 Chapel Street

South Yarra VIC, 3141Australia

(Address of Principal Executive Offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

INFORMATION CONTAINED IN THIS FORM 6-K REPORT

On December 9, 2025, Gelteq Limited (the “Company”) will be providing a virtual presentation hosted by Investor Summit to certain private investors. A copy of this presentation is furnished as Exhibit 99.1 to this Current Report on Form 6-K.

The foregoing (including Exhibit 99.1) will not be deemed to be filed for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise be subject to the liabilities of that section, nor will it be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act.

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKINGSTATEMENTS

This report on Form 6-K and the exhibits hereto contain “forward-looking statements” for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 that represent the Company’s beliefs, projections and predictions about future events. All statements other than statements of historical fact are “forward-looking statements,” including any projections of earnings, revenue or other financial items, any statements of the plans, strategies and objectives of management for future operations, any statements concerning proposed new projects or other developments, any statements regarding future economic conditions or performance, any statements of management’s beliefs, goals, strategies, intentions and objectives, and any statements of assumptions underlying any of the foregoing. Words such as “may”, “will”, “should”, “could”, “would”, “predicts”, “potential”, “continue”, “expects”, “anticipates”, “future”, “intends”, “plans”, “believes”, “estimates” and similar expressions, as well as statements in the future tense, identify forward-looking statements.

These statements are necessarily subjective and involve known and unknown risks, uncertainties and other important factors that could cause the Company’s actual results, performance or achievements, or industry results, to differ materially from any future results, performance or achievements described in or implied by such statements. Actual results may differ materially from expected results described in the Company’s forward-looking statements, including with respect to correct measurement and identification of factors affecting the Company’s business or the extent of their likely impact, and the accuracy and completeness of the publicly available information with respect to the factors upon which the Company’s business strategy is based or the success of the Company’s business.

Forward-looking statements should not be read as a guarantee of future performance or results, and will not necessarily be accurate indications of whether, or the times by which, the Company’s performance or results may be achieved. Forward-looking statements are based on information available at the time those statements are made and management’s belief as of that time with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. For a discussion of these risks and uncertainties, refer to Gelteq’s filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 20-F filed on November 17, 2025. Gelteq undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.

Financial Statements and Exhibits.

The following exhibits are being filed herewith:

ExhibitNumber	Description
99.1	Investor Presentation, dated December 9, 2025

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Gelteq Limited
By:	/s/ Nathan Givoni
Name:	Nathan Givoni
Title:	Chief Executive Officer

Date: December 9, 2025

Exhibit 99.1

FORWARD LOOKING STATEMENTS © Gelteq Limited 2025. All Rights Reserved. Proprietary & Confidential. Ce rt ain st a t emen ts in t hi s pr e s en t a t ion ma y con st i tut e “ fo rw a r d - looking st a t emen ts ” w i t hin t he meaning of t he P r i v a t e Sec ur i t ie s Li t iga t ion Refo r m Ac t of 1995. All st a t emen ts , o t he r t han st a t emen ts of hi st o r ical fac t , con t ained he r ein a r e fo rw a r d - looking st a t emen ts. Fo rw a r d - looking st a t emen ts in v ol v e kno w n and u nkno w n r i s k s , u nce rt ain t ie s , and o t he r fac t o rs t ha t ma y ca us e ac tu al r e su l ts t o diffe r ma t e r iall y f r om t ho s e e xpr e ss ed o r im p lied in su ch st a t emen ts. Fo r a di s c uss ion of t he s e r i s k s and u nce rt ain t ie s , r efe r t o Gel t e q ’ s filing s w i t h t he U . S . Sec ur i t ie s and E x change Commi ss ion (“ SEC ”), incl u ding i ts Ann u al Re p o rt on Fo r m 20 - F filed on No v embe r 17 , 2025. Gel t e q u nde rt ake s no obliga t ion t o up da t e an y fo rw a r d - looking st a t emen ts t o r eflec t e v en ts o r ci r c u m st ance s af t e r t he da t e he r eof .

A global clinical and s cience ba s ed com p an y t ha t ha s de v elo p ed a no v el d ru g deli v e ry p la t fo r m in an inge st ible gel fo r m Gel t e q sp eciali z e s in t he fo r m u la t ion , de v elo p men t and man u fac tur ing of gel pr od u c ts fo r licen s ed p a rt ne rs Fo u nded in 2017 in Melbo ur ne , A ustr alia , t he com p an y eme r ged f r om i ts fo u nde rs ’ w o r k a s a die t i t ian , aiming t o im pr o v e p a t ien t com p liance w i t h an ea sy t o sw allo w and enjo y able deli v e ry fo r ma t fo r medica t ion s and n utr i t ional supp lemen ts © Gelteq Limited 2025. All Rights Reserved. Proprietary & Confidential. GELTEQ ( NASDAQ : GELS ) OVERVIEW

GELTEQ - COMPANY HIGHLIGHTS Inno v a t i v e d ru g and n utr ien t deli v e ry p la t fo r m t ha t i s ma r ke t r ead y Po rt folio of n utr ace ut ical pr od u c ts al r ead y de v elo p ed and s ale s r ead y Gel t e q hold s m u l t i p le p a t en t familie s t ha t co v e r a r ange of a pp lica t ion s fo r o ur pr o pr ie t a ry gel t echnolog y Pilo t n utr ace ut ical o r de rs r ecen t l y deli v e r ed in China , USA and A ustr alia Di v e rs e API p i p eline a v ailable fo r R & D and licen s ing p a rt ne rs hi ps © Gelteq Limited 2025. All Rights Reserved. Proprietary & Confidential.

RESEARCH AND VALIDATION PARTNER Engaged Mona s h Uni v e rs i ty ’ s Medicine s Man u fac tur ing Inno v a t ion Cen tr e ( MMIC ) t o bo t h v e r if y and t e st o ur s cien t ifc me t hodologie s. Mona s h Uni v e rs i ty i s a global leade r in Pha r mace ut ical Science # 4 Pha r mac y and Pha r macolog y QS Ranking s 2025 ( Global )* Gel t e q ’ s s cien t i st t eam i s ba s ed in Mona s h Inno v a t ion Lab s w hich i s a g r o wt h and de v elo p men t eco syst em w i t hin Mona s h Uni v e rs i ty. © Gelteq Limited 2025. All Rights Reserved. Proprietary & Confidential. * h ttps :// www.t o pu ni v e rs i t ie s. com / u ni v e rs i ty - su bjec t - r anking s / p ha r mac y - p ha r macolog y

To im pr o v e t he li v e s of h u man s and animal s b y making d ru g and n utr ace ut ical pr od u c ts mo r e acce ss ible and ea s ie r t o con su me © Gelteq Limited 2025. All Rights Reserved. Proprietary & Confidential. MISSION STATEMENT

INDUSTRY CHALLENGES Pa t en t lifec y cle pr e ssur e s a s d ru g p a t en ts e xp i r e B r inging a 90% r e v en u e d r o p w hen gene r ic s a rr i v e ** Pill A v e rs ion and S w allo w ing i ssu e s ~40% of con su me rs stru ggle w i t h sw allo w ing supp lemen ts* Con v enience Con su me rs a r e demanding ne w, no v el and con v enien t fo r ma ts Poo r adhe r ence Lo w medica t ion adhe r ence mean s le ss in t ake and p oo r e r heal t h o ut come s C r o w ded ma r ke ts W i t h limi t ed o pt ion s fo r diffe r en t ia t ed deli v e ry fo r ma ts Inabili ty t o hold la r ge do s age s A v ailable e x i st ing fo r ma ts su ch a s g u mmie s, p ill s and ca psu le s can ’t hold la r ge do s age s * McClo s ke y , A . P . , Pen s on , P . E . , T s e , Y . , Abdelhafi z , M . A . , Ahmed , S . N . and Lim , E . J . , 2022. Iden t if y ing and add r e ss ing p ill a v e rs ion in ad u l ts w i t ho ut p h ys iological - r ela t ed d ysp hagia : A na rr a t i v e r e v ie w. B r i t i s h Jo ur nal of Clinical Pha r macolog y , 88 ( 12 ), pp.5128 - 5148. ** R u mo r e , M . M . and Vogenbe r g , F . R . , 2016. Bio s imila rs : st ill no t qu i t e r ead y fo r pr ime t ime . Pha r mac y and The r a p e ut ic s , 41 ( 6 ), p.366. © Gelteq Limited 2025. All Rights Reserved. Proprietary & Confidential. Challenge s t ha t p ha r mace ut ical & supp lemen t com p anie s a r e facing

The o r al deli v e ry of oil - s ol u ble ( li p o p hilic ) o r in s ol u ble com p o u nd s a r e a majo r challenge fo r p ha r mace ut ical com p anie s. 40 – 60 % of ma r ke t ed d ru g s and up t o 90 % of di s co v e ry candida t e s a r e p oo r l y s ol u ble * Pha r mace ut ical com p anie s a r e al r ead y in v e st ing ~ USD $ 4 - 7 Bn ann u all y in t echnologie s t ha t im pr o v e deli v e ry of p oo r l y s ol u ble / oil y d ru g s ** INDUSTRY CHALLENGES * Xie , B . , Li u , Y . , Li , X . , Yang , P . and He , W . , 2024. Sol u bili z a t ion t echni qu e s us ed fo r p oo r l y w a t e r - s ol u ble d ru g s. Ac t a Pha r mace ut ica Sinica B , 14 ( 11 ), pp.4683 - 4716. ** Sol u bili ty Enhancemen t E x ci p ien ts Ma r ke t Si z e 2025 - 2032 h ttps :// s ha r e . google / DUYk 0 RWZb 7 Z 9 m u U 3 g © Gelteq Limited 2025. All Rights Reserved. Proprietary & Confidential.

Imagine if t he r e w a s an inno v a t i v e deli v e ry p la t fo r m t ha t co u ld add r e ss t he challenge s t ha t p ha r mace ut ical and n utr ace ut ical com p anie s a r e e xp e r iencing © Gelteq Limited 2025. All Rights Reserved. Proprietary & Confidential. IMAGINE

THE GELTEQ SOLUTION © Gelteq Limited 2025. All Rights Reserved. Proprietary & Confidential. Gel t e q ’ s p a t en t ed gel deli v e ry can p o t en t iall y syst em s ol v e man y of t he p ha r mace ut ical and supp lemen t ind ustry ’ s challenge s - f r om p oo r adhe r ence and p ill fa t ig u e t o t he o r al deli v e ry of in s ol u ble ing r edien ts O ur gel s can incl u de s ingle o r m u l t i p le w a t e r s ol u ble , fine in s ol u ble and oil - s ol u ble ing r edien ts Thi s can incl u de v i t amin s , mic r o and mac r o n utr ien ts , he r bal e xtr ac ts and ac t i v e p ha r mace ut ical ing r edien ts ( API s ), in a s ingle s helf - st able gel w i t h a u nifo r m t e xtur e and com p o s i t ion

T r ial r e su l ts s ho w ed Gel t e q ’ s inno v a t i v e t echnolog y fo r w a t e r s ol u ble com p o u nd s w a s able t o : Im pr o v e bioa v ailabili ty ( o v e r all ab s o rpt ion ) b y o v e r 40 % . P r o v ide fa st e r ab s o rpt ion fo r an API Enhance ing r edien t ab s o rpt ion w hich can deli v e r s ignifican t l y im pr o v ed effec t i v ene ss of t he d ru g Inc r ea s e p eak concen tr a t ion s The demon str a t ed bioa v ailabili ty enhancemen ts b y a s ignifican t ma r gin pr o v ide s a str ong fo u nda t ion fo r a pp l y ing Gel t e q ’ s p la t fo r m ac r o ss m u l t i p le o t he r w a t e r - s ol u ble d ru g cla ss e s , w i t h t he p o t en t ial t o e xp and t he Com p an y ’ s comme r cial s co p e Graph = Gelteq trial results with a water soluble drug and FDA approved product GELTEQ ADVANTAGES - WATER SOLUBLE COMPOUNDS Plasma concentration Water soluble drug in Gelteq gel Water soluble drug with water time post - administration (hours) © Gelteq Limited 2025. All Rights Reserved. Proprietary & Confidential.

GELTEQ ADVANTAGES - OIL SOLUBLE COMPOUNDS time post - administration (hours) Graph = Gelteq trial results with an oil soluble drug and FDA approved product T r ial r e su l ts s ho w ed Gel t e q ’ s inno v a t i v e t echnolog y fo r oil s ol u ble com p o u nd s w a s able t o : Ha v e 300 % fa st e r ab s o rpt ion of an API in t he fi rst ho ur w hich can can deli v e r s ignifican t l y im pr o v ed efficienc y of t he d ru g Im pr o v e bioa v ailabili ty ( o v e r all ab s o rpt ion ) b y o v e r 20 % . Inc r ea s e p eak concen tr a t ion s The enhanced bioa v ailabili ty and sp eed of ab s o rpt ion pr o v ide s a str ong fo u nda t ion fo r a pp l y ing Gel t e q ’ s p la t fo r m ac r o ss m u l t i p le o t he r oil - s ol u ble d ru g cla ss e s and add r e ss ing a ke y ind ustry need Plasma concentration Oil soluble drug in Gelteq gel Oil soluble drug © Gelteq Limited 2025. All Rights Reserved. Proprietary & Confidential.

GELTEQ IS REIMAGINING THE ADMINISTERED DOSE © Gelteq Limited 2025. All Rights Reserved. Proprietary & Confidential. Gel t e q pr od u c ts can be deli v e r ed in a w ell e st abli s hed p ackaging fo r ma t t ha t i s w ell ado pt ed in t he ma r ke t... d r i v en b y con v enience VS

GELTEQ CAN SOLVE INDUSTRY CHALLENGES © Gelteq Limited 2025. All Rights Reserved. Proprietary & Confidential. Pa t en t lifec y cle pr e ssur e s a s d ru g p a t en ts e xp i r e Pill A v e rs ion and S w allo w ing i ssu e s Con v enience Poo r adhe r ence C r o w ded ma r ke ts Inabili ty t o hold la r ge do s age s * McClo s ke y , A . P . , Pen s on , P . E . , T s e , Y . , Abdelhafi z , M . A . , Ahmed , S . N . and Lim , E . J . , 2022. Iden t if y ing and add r e ss ing p ill a v e rs ion in ad u l ts w i t ho ut p h ys iological - r ela t ed d ysp hagia : A na rr a t i v e r e v ie w. B r i t i s h Jo ur nal of Clinical Pha r macolog y , 88 ( 12 ), pp.5128 - 5148. ** R u mo r e , M . M . and Vogenbe r g , F . R . , 2016. Bio s imila rs : st ill no t qu i t e r ead y fo r pr ime t ime . Pha r mac y and The r a p e ut ic s , 41 ( 6 ), p.366. GELTEQ CAN ADRESSES KEY CHALLENGES PHARMACEUTICAL & SUPPLEMENT COMPANIES ARE FACING

GELTEQ MARKETS © Gelteq Limited 2025. All Rights Reserved. Proprietary & Confidential. Gel t e q ’ s p la t fo r m i s able t o w o r k ac r o ss t he belo w v e rt ical s. We offe r a com p le t e end - t o - end s e rv ice fo r o ur licen s ed p a rt ne rs. HUMAN HEALTH H u man Pha r mace ut ical H u man N utr ace ut ical ANIMAL HEALTH Animal Pha r mace ut ical Animal N utr ace ut ical

2024 2030 0 500 1000 1500 2000 2024 2034 0 500 1000 1500 2000 MARKET OPPORTUNITY ( HUMAN HEALTH ) The global p ha r mace ut ical ma r ke t Global n utr ace ut ical / supp lemen t ma r ke t $ 1 , 645.7 B $ 591.1 B 6.12 % CAGR 7.6 % CAGR $ 2 , 350.4 B $ 919.1 B So ur ce: G r and Vie w Re s ea r ch . ( 2025 ) . N utr ace ut ical s ma r ke t s i z e, s ha r e & tr end s anal ys i s r e p o rt , 2025 - 2030. © Gelteq Limited 2025. All Rights Reserved. Proprietary & Confidential. So ur ce: G r and Vie w Re s ea r ch . ( 2025 ) . Pha r mace ut ical Ma r ke t ( 2025 - 2030 ) .

2024 2035 35 30 25 20 15 10 5 0 MARKET OPPORTUNITY ( ANIMAL HEALTH ) Global p e t p ha r mace ut ical ma r ke t $ 13.2B 7.85% CAGR $ 30.3B Gelteq makes supplement and medication delivery simple and stress - free for pets , pet owners , and veterinarians alike. 2023 2030 © Gelteq Limited 2025. All Rights Reserved. Proprietary & Confidential. 35 30 25 20 15 10 5 0 Global p e t n utr ace ut ical / supp lemen t ma r ke t $ 6.8 B 6.4% CAGR $ 10.5 B So ur ce: G r and Vie w Re s ea r ch . ( 2023 ) . Global p e t n utr ace ut ical s ma r ke t s i z e & o ut look, 2023 - 2030. So ur ce: Me t a t ech In s igh ts. ( 2024 ) . Pe t Pha r mace ut ical s ma r ke t s i z e, s ha r e & fo r eca st 2025 - 2035 (Re p o rt ID: MI 1173 )

O ur str a t eg y i s t o p a rt ne r w i t h p ha r mace ut ical and supp lemen t com p anie s t o de v elo p ʁ man u fac tur e ʁ and licen s e gel ʉ ba s ed pr od u c ts. © Gelteq Limited 2025. All Rights Reserved. Proprietary & Confidential. GELTEQ B 2 B STRATEGY We a r e c urr en t l y foc us ed on demon str a t ing t he ca p abili t ie s of o ur d ru g deli v e ry p la t fo r m t o pr o sp ec t i v e p ha r mace ut ical com p anie s w ho can licen s e o ur t echnolog y fo r ne w pr od u c t s ale s Pha r mace ut ical Com p anie s S upp lemen t / N utr ace ut ical Com p anie s We a r e ac t i v el y engaging w i t h n utr ace ut ical ʤ supp lemen t com p anie s t o licen s e pr od u c ts f r om o ur p o rt folio of gel pr od u c ts. We al s o de v elo p c ust om gel fo r m u la t ion s t ailo r ed t o sp ecific need s.

RESEARCH & DEVELOPMENT PIPELINE SNAPSHOT © Gelteq Limited 2025. All Rights Reserved. Proprietary & Confidential. Pain Managemen t Alle r g y Diabe t e s Weigh t Managemen t Medicinal Cannabi s Men t al Heal t h Refl ux ( GERD ) An t i p a r a s i t ic Ve t e r ina r ian Oncolog y GeRX - 761 GeRX - 561 GeRX - 461 GeR x - 481 GeR x - 081 GeRX - 261 GeRX - 681 GeRx - 941 GeRX - 341 H u man Animal Di s co v e ry P r e Clinical Clinical Reg u la t o ry A ppr o v ed O pt imi s a t ion

Da rr o w A ss ocia t e s Ma tt K r e ps Managing Di r ec t o r A ust in, Te x a s Uni t ed S t a t e s T: 214 - 597 - 8200 mk r e ps @ da rr o w i r. com In v e st o r Rela t ion s Gel t e q Na t han Gi v oni, CEO Mona s h Inno v a t ion Lab s G .60 , 22 Alliance Lane Cla yt on 3800 Vic t o r ia A ustr alia T: + 61 3 9087 3990 i r @gel t e q. com h ttps :// www. gel t e q. com Com p an y © Gelteq Limited 2025. All Rights Reserved. Proprietary & Confidential.